# Absci

runs Origin-1, a generative AI platform for de novo antibody design against novel epitopes, and collaborated with Twist Bioscience to combine generative-AI drug creation with DNA synthesis.


Source: https://en.bioecon.ru/companies/absci/
Updated: 2026-08-17

- Country: United States
- Ticker: NASDAQ:ABSI

## Technologies

- [AI strain-design & engineering platforms](https://en.bioecon.ru/technology/ai-strain-design-engineering-platforms/)